SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ: 095700), a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that Neil Warma, CEO of Genexine will be presenting virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.
The presentation will provide an overview of Genexine’s pipeline, business operations and corporate achievements, as well as discuss upcoming milestones with the Company’s lead assets, including GX-I7 (a first-in-class long-acting recombinant interleukin 7, in development for TNBC and GBM) and GX-188 (a first-in-class DNA vaccine, in development for cervical and head and neck cancers).
Details of the presentation are as follows:
Event: H.C. Wainwright Global Investment Conference
Date & Time: On-demand, beginning 7.00 a.m. ET, Tuesday May 24, 2022
Webcast Link: Genexine_Wainwright_investor_conf.
A replay of the presentation will be available for 90 days at the link above or by visiting www.genexine.com. Registered investors will be able to schedule a one-on-one meeting via the conference portal.
Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technology platforms are Therapeutic DNA vaccine technology and hyFcTM fusion technology. The Company has multiple products in clinical development including several undergoing Phase 3 registrational trials. The Company's proprietary pipeline includes GX-188 for cervical and head and neck cancer, GX-I7 for multiple cancers, GX-H9 for Pediatric Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide.